Synalar contains fluocinolone acetonide, a topical corticosteroid that calms excessive inflammation in the skin. It is used for corticosteroid-responsive conditions such as eczema, dermatitis and selected psoriasis flares. The ointment reduces redness, swelling and itching when applied thinly to the affected area for the prescribed duration.
Synalar is a topical corticosteroid ointment containing fluocinolone acetonide at a strength of 0.025%. Fluocinolone acetonide is the active ingredient responsible for reducing inflammatory activity.
Fluocinolone acetonide belongs to the corticosteroid class. Corticosteroids reduce excessive immune and inflammatory activity rather than removing every underlying cause of a skin condition.
Apply a thin layer of Synalar to the affected skin at the prescribed frequency. The regimen for the chosen strength should be confirmed with a healthcare professional before starting.
More ointment does not make inflamed skin heal faster. A thick coating increases exposure and may raise the risk of local adverse effects.
The fingertip-unit method can help estimate the amount needed when a clinician has explained it. The correct quantity depends on the size of the affected area and the body site. Children often need smaller quantities because their skin-to-body-size ratio is higher.
Do not cover Synalar with a bandage, plastic wrap or another occlusive dressing unless this has been specifically prescribed. Occlusion can increase penetration through the skin.
Use Synalar at the frequency prescribed for the diagnosed condition. There is no single course length suitable for every rash, body site or age group.
If an application is missed, apply it when remembered unless the next scheduled application is close. Do not apply a double amount to compensate. If symptoms improve early, do not extend, restart or intensify treatment without a clinical review.
Synalar is a topical corticosteroid ointment containing fluocinolone acetonide at a strength of 0.025%. It is supplied in tubes and applied directly to affected skin. Fluocinolone acetonide is the active ingredient responsible for reducing inflammatory activity.
The 0.025% strength represents the concentration of fluocinolone acetonide in the ointment. It should not be confused with the pack size, which is measured separately in grams. Topical corticosteroids act in the skin and are pharmacologically different from anabolic steroids used to influence muscle growth.
Fluocinolone acetonide belongs to the corticosteroid class. Corticosteroids reduce excessive immune and inflammatory activity rather than removing every underlying cause of a skin condition.
Synalar may be prescribed when inflammation causes symptoms such as:
It is for external use only.
Fluocinolone acetonide enters skin cells and activates glucocorticoid receptors. This changes the expression of inflammatory mediators and reduces signalling that contributes to redness, swelling and itching. The pharmacological action is consistent with the recognised anti-inflammatory effects of topical corticosteroids [2].
In plain language, Synalar quietens an overactive inflammatory response in the treated skin. It does not kill bacteria, fungi or viruses. It also does not permanently remove the tendency to eczema or psoriasis, so symptoms can return after a course ends.
As inflammation settles, the skin may feel less hot and itchy. Redness and swelling can also become less pronounced. Relief does not always mean that the underlying skin condition has fully resolved.
Synalar is used for inflammatory or allergic skin conditions that respond to topical corticosteroids. These can include eczema, dermatitis and selected localised psoriasis flares. The appropriate choice depends on the diagnosis, body site, severity, age and presence of infection [1].
| Condition | Typical inflammatory features | Clinical role of Synalar |
|---|---|---|
| Eczema | Itching, redness, dryness and irritation | Helps control an inflammatory flare |
| Dermatitis | Red, itchy or swollen skin after irritation or allergy | Reduces inflammatory symptoms |
| Localised psoriasis | Well-defined plaques with scaling | May help during selected flares |
A spreading rash, increasing pain, warmth, pus, crusting or fever needs medical assessment. Those features can indicate infection or another condition requiring a different treatment approach. Corticosteroid treatment alone may allow some infections to worsen.
During an eczema flare, Synalar can reduce itching and redness while the skin barrier recovers. Emollients remain useful for everyday moisturising, even when a corticosteroid is prescribed. Use the emollient and Synalar as separate applications according to the instructions provided for the treatment plan.
Contact dermatitis can result from irritants such as detergents, solvents or frequent hand washing. It can also follow an allergic reaction to a substance touching the skin. Removing the trigger remains part of management; Synalar controls the inflammatory response but does not remove the trigger.
Synalar may be used for selected areas of psoriasis when inflammation is localised and the formulation is suitable. Facial, genital, skin-fold or widespread psoriasis needs a specific clinical plan because these sites absorb topical corticosteroids more readily or require different treatment choices.
Do not apply it to acne, rosacea or an undiagnosed rash unless a clinician has identified a corticosteroid-responsive condition.
These situations do not all represent absolute contraindications, but they change the risk assessment. Infection may need antimicrobial treatment rather than corticosteroid treatment alone. Occlusion can increase absorption, while thin skin can be more susceptible to thinning and irritation.
Do not exceed the prescribed dosage or application frequency. Contact a doctor after accidental heavy use, especially when the affected area is large or treatment has continued for longer than intended.
NOT for you if:
Topical corticosteroids can cause local irritation, burning, itching or redness. These effects may be mild and short-lived, but persistent or worsening symptoms require assessment. Fluocinolone acetonide can also cause skin thinning, stretch marks, increased visibility of small blood vessels or changes in skin colour, especially after prolonged use or application to sensitive areas [3].
Risk increases with:
Stop improvising with the treatment if the skin becomes markedly more painful, swollen, blistered or weepy. A new rash after application may indicate irritation or contact allergy to the active ingredient or an excipient.
Improvement is not a reason to continue treatment indefinitely. The goal is to use the smallest amount for the prescribed period that controls the diagnosed flare.
Accidental use of a small excess amount is unlikely to cause serious harm, but repeated heavy application should be avoided. Contact a doctor or pharmacist promptly after substantial overuse, use over a very large area or prolonged use under an occlusive dressing.
Extensive or prolonged exposure can allow corticosteroid absorption into the bloodstream. Rarely, this may affect adrenal or hormonal function. Children are more vulnerable because a greater skin surface may be treated relative to body size.
Synalar ointment has a more occlusive, greasy base than a cream. This can suit dry, cracked or heavily scaly skin because the base helps retain moisture. A cream may feel lighter and spread more easily, but it can sting more on severely irritated skin depending on its excipients.
| Feature | Cream | Ointment |
|---|---|---|
| Texture | Lighter and easier to spread | Greasier and more occlusive |
| Common practical use | Areas where a lighter feel is preferred | Dry, thickened or scaly areas |
| Main caution | May sting irritated skin | May feel heavy and transfer to clothing |
Neither form is universally superior. The active ingredient and strength must still match the clinical plan. Do not change between cream and ointment solely because one feels more comfortable.
In clinical practice, doctors usually focus on four details before prescribing a topical corticosteroid: the diagnosis, the site, the strength and the duration. The amount applied is only one part of safe treatment.
A common prescribing mistake is treating a new rash as if it were the same as a previous eczema flare. Fungal infections, scabies, perioral dermatitis and bacterial infections can look inflamed but require different management. The wrong topical steroid can temporarily reduce redness while allowing the cause to persist.
Clinicians also pay close attention to the face, eyelids, groin, armpits and skin folds. These areas can absorb corticosteroids more readily and may develop local adverse effects sooner. Children need careful quantity and duration guidance for the same reason.
Stop using Synalar and seek prompt medical advice if the treated area becomes rapidly more painful, swollen, blistered or covered with pus. Facial swelling, breathing difficulty or widespread hives may indicate a serious allergic reaction and need urgent assessment. NICE eczema guidance published in 2023 advises medical review when skin inflammation is accompanied by infection signs or systemic illness [4].
Itching and redness may begin to settle after several applications, though the timing varies with the diagnosis, severity and body site. A lack of improvement, rapid worsening or spread suggests that the diagnosis or treatment plan needs review. The MHRA’s topical corticosteroid safety information published in 2021 supports using these medicines for the intended course rather than extending treatment because improvement is slow.
The clinical effect depends on the strength, formulation, skin condition and application schedule. Ointment remains on the skin longer than a quickly removed product, but this does not mean that extra applications are appropriate. The FDA’s 2020 prescribing information explains that fluocinolone acetonide acts through local glucocorticoid receptors, so the prescribed frequency should be followed rather than adjusted according to how greasy the skin feels.
The course length depends on the affected area, diagnosis, age and response. Long-term continuous use should not be assumed to be appropriate because repeated exposure can increase the risk of skin thinning and systemic absorption. The 2025 British National Formulary describes topical corticosteroid treatment as requiring selection of suitable potency, site and duration rather than indefinite self-treatment.
Regular emollient use can support the skin barrier in eczema, while irritants such as fragranced products, harsh detergents and repeated wet work can maintain inflammation. Scratching can worsen skin damage and increase the risk of infection. The World Health Organization’s 2002 practical approach to rational medicine use supports matching treatment to the confirmed condition and avoiding unnecessary escalation.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The product described here is Synalar ointment 0.025% supplied in tubes. Ointment is a semi-solid preparation designed to remain on the skin and provide an occlusive, moisturising base.
Synalar names can refer to different presentations in different markets. Cream, ointment and combination products may not contain the same ingredients or have the same strength. A similarly named presentation should never be substituted without confirming its active ingredients and concentration.
Ointment is often useful on dry, thickened or scaly skin because its greasy base helps reduce water loss. It may feel heavy on hairy areas or during warm weather. Some people prefer a cream texture for daytime use, but the base does not determine corticosteroid potency by itself.
Potency depends on the active ingredient, concentration and formulation. A lighter-feeling preparation is not automatically weaker, and a greasier preparation is not automatically stronger.
Synalar ointment 0.025% contains fluocinolone acetonide at the stated concentration. Pack size and active-ingredient strength are separate facts. A larger tube does not contain a stronger medicine.
Named presentations with additional letters or antimicrobial ingredients may have a different composition. They should not be treated as interchangeable with Synalar ointment.
Synalar ointment is used for inflammatory skin disease. An antimicrobial-containing presentation may be selected when a clinician identifies a specific infection risk or secondary infection. The full formulation and diagnosis must match before either product is used.
The itching eased within several days and the cracks became less uncomfortable. I found the ointment greasy during the day, so I used it when I was staying in rather than before work.
The redness settled, but the first application tingled for a few minutes. I stopped when the skin became more sore and arranged a review instead of carrying on with the tube.
It helped the itching, though the patch returned after I stopped. The useful part was having the area reassessed rather than repeatedly applying the same ointment.
